» Articles » PMID: 38256663

Venous Thromboembolism in Patients Hospitalized for COVID-19 in a Non-Intensive Care Unit

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Jan 23
PMID 38256663
Authors
Affiliations
Soon will be listed here.
Abstract

Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may contribute to venous thromboembolism (VTE) with adverse effects on the course of COVID-19. The purpose of this study was to investigate an incidence and risk factors for VTE in patients hospitalized for COVID-19 in a non-intensive care unit (non-ICU). Consecutive adult patients with COVID-19 hospitalized from November 2021 to March 2022 in the isolation non-ICU at our center were included in the study. Incidence of VTE including pulmonary embolism (PE) and deep vein thrombosis (DVT), clinical characteristics, and D-dimer plasma levels during the hospitalization were retrospectively evaluated. Among the 181 patients (aged 68.8 ± 16.2 years, 44% females, 39% Delta SARS-CoV-2 variant, 61% Omicron SARS-CoV-2 variant), VTE occurred in 29 patients (VTE group, 16% of the entire cohort). Of them, PE and DVT were diagnosed in 15 (8.3% of the entire cohort) and 14 (7.7%) patients, respectively. No significant differences in clinical characteristics were observed between the VTE and non-VTE groups. On admission, median D-dimer was elevated in both groups, more for VTE group (1549 ng/mL in VTE vs. 1111 ng/mL in non-VTE, = 0.09). Median maximum D-dimer was higher in the VTE than in the non-VTE group (5724 ng/mL vs. 2200 ng/mL, < 0.005). In the univariate analysis, systemic arterial hypertension and the need for oxygen therapy were predictors of VTE during hospitalization for COVID-19 (odds ratio 2.59 and 2.43, respectively, < 0.05). No significant associations were found between VTE risk and other analyzed factors; however, VTE was more likely to occur in patients with a history of VTE, neurological disorders, chronic pulmonary or kidney disease, atrial fibrillation, obesity, and Delta variant infection. Thromboprophylaxis (83.4% of the entire cohort) and anticoagulant treatment (16.6%) were not associated with a decreased VTE risk. The incidence of VTE in patients hospitalized in non-ICU for COVID-19 was high despite the common use of thromboprophylaxis or anticoagulant treatment. A diagnosis of arterial hypertension and the need for oxygen therapy were associated with an increased VTE risk. Continuous D-dimer monitoring is required for the early detection of VTE.

Citing Articles

Analysis of Deep Vein Thrombosis: A Prospective Observational Study.

Ali I, Reddy M V, Shetty V Cureus. 2024; 16(8):e68014.

PMID: 39347152 PMC: 11430053. DOI: 10.7759/cureus.68014.

References
1.
Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen P . Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2007; 117(1):93-102. DOI: 10.1161/CIRCULATIONAHA.107.709204. View

2.
Porfidia A, Valeriani E, Pola R, Porreca E, Rutjes A, Di Nisio M . Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb Res. 2020; 196:67-74. PMC: 7420982. DOI: 10.1016/j.thromres.2020.08.020. View

3.
Goshua G, Pine A, Meizlish M, Chang C, Zhang H, Bahel P . Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020; 7(8):e575-e582. PMC: 7326446. DOI: 10.1016/S2352-3026(20)30216-7. View

4.
Sholzberg M, Tang G, Rahhal H, AlHamzah M, Kreuziger L, Ainle F . Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021; 375:n2400. PMC: 8515466. DOI: 10.1136/bmj.n2400. View

5.
Gupta N, Zhao Y, Evans C . The stimulation of thrombosis by hypoxia. Thromb Res. 2019; 181:77-83. DOI: 10.1016/j.thromres.2019.07.013. View